GenBioPro Sues FDA To Keep Generic Mifepristone Available; Supreme Court Delays Its Decision
Executive Summary
GenBioPro asks Maryland district court to prevent FDA from taking enforcement actions against it if Supreme Court allows stay of approval of mifepristone. Justice Samuel Alito extends deadline to respond until midnight Friday.
You may also be interested in...
Supreme Court’s Stay Of Mifepristone Ruling Gives FDA Respite For Next Round
Medication abortion pill can remain on the market under current conditions until appeal on the merits of the preliminary injunction is decided. Justice Alito dissents, noting that FDA could exercise its enforcement discretion to prevent harm to mifepristone manufacturer Danco.
GenBioPro Suit Against FDA May Preserve Generic Mifepristone Approval
GenBioPro has filed a lawsuit against the FDA to try and preserve the approval of its generic mifepristone product, should the Supreme Court allow an order from a Texas judge to overrule the Food and Drug Administration’s approval of the drug.
PhRMA Jumps Into Battle Over Mifepristone Regulation With Supreme Court Filing
After sitting out the initial rounds, trade group backs FDA’s decisions on the medication abortion pill and asks Supreme Court to stay Texas district court ruling suspending the drug’s approval.
| Table |
|---|